Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 2046545, 10 pages
https://doi.org/10.1155/2017/2046545
Research Article

MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis

1Second Department of Internal Medicine and Research Unit, University General Hospital “Attikon”, 1 Rimini St., Haidari, 12462 Athens, Greece
2Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, Panepistimiopolis, 15701 Athens, Greece

Correspondence should be addressed to Christos K. Kontos; rg.aou.loib@sotnokhc

Received 26 September 2017; Accepted 20 November 2017; Published 31 December 2017

Academic Editor: Alvaro González

Copyright © 2017 Sotirios G. Papageorgiou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Chiorazzi, K. R. Rai, and M. Ferrarini, “Chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 352, no. 8, pp. 804–815, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. G. D'Arena, N. Di Renzo, M. Brugiatelli, M. L. Vigliotti, and M. J. Keating, “Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia,” Leukemia & Lymphoma, vol. 44, no. 2, pp. 223–228, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Eichhorst, M. Dreyling, T. Robak, E. Montserrat, M. Hallek, and E. G. W. Group, “Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 22, Supplement 6, pp. vi50–vi54, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. K. R. Rai, A. Sawitsky, E. P. Cronkite, A. D. Chanana, R. N. Levy, and B. S. Pasternack, “Clinical staging of chronic lymphocytic leukemia,” Blood, vol. 46, no. 2, pp. 219–234, 1975. View at Google Scholar
  5. J. L. Binet, A. Auquier, G. Dighiero et al., “A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis,” Cancer, vol. 48, no. 1, pp. 198–206, 1981. View at Publisher · View at Google Scholar
  6. M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Moreno and E. Montserrat, “New prognostic markers in chronic lymphocytic leukemia,” Blood Reviews, vol. 22, no. 4, pp. 211–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Crespo, F. Bosch, N. Villamor et al., “ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 348, no. 18, pp. 1764–1775, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. T. J. Hamblin, J. A. Orchard, R. E. Ibbotson et al., “CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease,” Blood, vol. 99, no. 3, pp. 1023–1029, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. T. L. Parker and M. P. Strout, “Chronic lymphocytic leukemia: prognostic factors and impact on treatment,” Discovery Medicine, vol. 11, no. 57, pp. 115–123, 2011. View at Google Scholar
  11. M. A. Valencia-Sanchez, J. Liu, G. J. Hannon, and R. Parker, “Control of translation and mRNA degradation by miRNAs and siRNAs,” Genes & Development, vol. 20, no. 5, pp. 515–524, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Esquela-Kerscher and F. J. Slack, “Oncomirs — microRNAs with a role in cancer,” Nature Reviews Cancer, vol. 6, no. 4, pp. 259–269, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Balatti, Y. Pekarky, and C. M. Croce, “Role of microRNA in chronic lymphocytic leukemia onset and progression,” Journal of Hematology & Oncology, vol. 55, no. 6, pp. 1227–1239, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Mirzaei, S. Fathullahzadeh, R. Khanmohammadi et al., “State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia,” Journal of Cellular Physiology, vol. 233, no. 2, pp. 888–900, 2017. View at Publisher · View at Google Scholar
  15. I. Faraoni, F. R. Antonetti, J. Cardone, and E. Bonmassar, “miR-155 gene: a typical multifunctional microRNA,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1792, no. 6, pp. 497–505, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Yang, J. Wang, M. Xiao, T. Zhou, and X. Shi, “Role of mir-155 in controlling HIF-1α level and promoting endothelial cell maturation,” Scientific Reports, vol. 6, article 35316, no. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. U. Bruning, L. Cerone, Z. Neufeld et al., “MicroRNA-155 promotes resolution of hypoxia-inducible factor 1α activity during prolonged hypoxia,” Molecular and Cellular Biology, vol. 31, no. 19, pp. 4087–4096, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. Brown and W. R. Wilson, “Exploiting tumour hypoxia in cancer treatment,” Nature Reviews Cancer, vol. 4, no. 6, pp. 437–447, 2004. View at Publisher · View at Google Scholar
  19. V. Mucaj, J. E. Shay, and M. C. Simon, “Effects of hypoxia and HIFs on cancer metabolism,” International Journal of Hematology, vol. 95, no. 5, pp. 464–470, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Tili, C. M. Croce, and J. J. Michaille, “miR-155: on the crosstalk between inflammation and cancer,” International Reviews of Immunology, vol. 28, no. 5, pp. 264–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Tili, J. J. Michaille, and C. M. Croce, “MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer,” Immunological Reviews, vol. 253, no. 1, pp. 167–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Vigorito, S. Kohlhaas, D. Lu, and R. Leyland, “miR-155: an ancient regulator of the immune system,” Immunological Reviews, vol. 253, no. 1, pp. 146–157, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. C. H. Yeh, R. Moles, and C. Nicot, “Clinical significance of microRNAs in chronic and acute human leukemia,” Molecular Cancer, vol. 15, no. 1, p. 37, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Costinean, N. Zanesi, Y. Pekarsky et al., “Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 18, pp. 7024–7029, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. S. Elton, H. Selemon, S. M. Elton, and N. L. Parinandi, “Regulation of the MIR155 host gene in physiological and pathological processes,” Gene, vol. 532, no. 1, pp. 1–12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. C. K. Kontos, S. G. Papageorgiou, M. A. Diamantopoulos et al., “mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): an independent predictor of poor overall survival in chronic lymphocytic leukemia,” Leukemia Research, vol. 53, pp. 65–73, 2017. View at Publisher · View at Google Scholar
  27. M. A. Diamantopoulos, C. K. Kontos, D. Kerimis, I. N. Papadopoulos, and A. Scorilas, “Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients,” Clinical Chemistry and Laboratory Medicine, vol. 55, no. 5, pp. 737–747, 2017. View at Publisher · View at Google Scholar
  28. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. T. D. Schmittgen and K. J. Livak, “Analyzing real-time PCR data by the comparative CT method,” Nature Protocols, vol. 3, no. 6, pp. 1101–1108, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. L. Camp, M. Dolled-Filhart, and D. L. Rimm, “X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization,” Clinical Cancer Research, vol. 10, no. 21, pp. 7252–7259, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Vasilatou, S. Papageorgiou, V. Pappa, E. Papageorgiou, and J. Dervenoulas, “The role of microRNAs in normal and malignant hematopoiesis,” European Journal of Haematology, vol. 84, no. 1, pp. 1–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. C. K. Kontos, D. Vasilatou, S. G. Papageorgiou, and A. Scorilas, “Translation regulation by microRNAs in acute leukemia,” Reviews in Cell Biology and Molecular Medicine, Wiley-VCH Verlag GmbH & Co. KGaA, 2006. View at Google Scholar
  33. M. Fabbri, C. M. Croce, and G. A. Calin, “MicroRNAs in the ontogeny of leukemias and lymphomas,” Leukemia & Lymphoma, vol. 50, no. 2, pp. 160–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. T. H. Thai, D. P. Calado, S. Casola et al., “Regulation of the germinal center response by microRNA-155,” Science, vol. 316, no. 5824, pp. 604–608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Rodriguez, E. Vigorito, S. Clare et al., “Requirement of bic/microRNA-155 for normal immune function,” Science, vol. 316, no. 5824, pp. 608–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Ling, J. Gu, Z. Lei et al., “microRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma,” Oncology Reports, vol. 30, no. 5, pp. 2111–2118, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Miyamoto, K. Y. Araki, K. Naka et al., “Foxo3a is essential for maintenance of the hematopoietic stem cell pool,” Cell Stem Cell, vol. 1, no. 1, pp. 101–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Faraoni, S. Laterza, D. Ardiri, C. Ciardi, F. Fazi, and F. Lo-Coco, “MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status,” Journal of Hematology & Oncology, vol. 5, no. 1, p. 26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Garzon, S. Volinia, C. G. Liu et al., “MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia,” Blood, vol. 111, no. 6, pp. 3183–3189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Jongen-Lavrencic, S. M. Sun, M. K. Dijkstra, P. J. Valk, and B. Lowenberg, “MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia,” Blood, vol. 111, no. 10, pp. 5078–5085, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. P. Whitman, K. Maharry, M. D. Radmacher et al., “FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study,” Blood, vol. 116, no. 18, pp. 3622–3626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. R. M. O'Connell, D. S. Rao, A. A. Chaudhuri et al., “Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder,” The Journal of Experimental Medicine, vol. 205, no. 3, pp. 585–594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Vargova, M. Pesta, P. Obrtlikova et al., “MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia,” Blood Cancer Journal, vol. 7, no. 7, article e585, 2017. View at Publisher · View at Google Scholar
  44. K. Szurian, I. Csala, V. Piurko, L. Deak, A. Matolcsy, and L. Reiniger, “Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma – proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression,” Leukemia Research, vol. 58, pp. 39–42, 2017. View at Publisher · View at Google Scholar
  45. F. M. Furtado, P. S. Scheucher, B. A. Santana et al., “Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia,” Revista Brasileira de Hematologia e Hemoterapia, vol. 39, no. 3, pp. 237–243, 2017. View at Publisher · View at Google Scholar
  46. S. Malek, “Molecular biomarkers in chronic lymphocytic leukemia,” Advances in Experimental Medicine and Biology, vol. 792, pp. 193–214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. N. Damle, T. Wasil, F. Fais et al., “Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia,” Blood, vol. 94, no. 6, pp. 1840–1847, 1999. View at Google Scholar
  48. T. Zenz, A. Krober, K. Scherer et al., “Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up,” Blood, vol. 112, no. 8, pp. 3322–3329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. M. I. Del Principe, G. Del Poeta, F. Buccisano et al., “Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia,” Blood, vol. 108, no. 3, pp. 853–861, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Del Poeta, L. Maurillo, A. Venditti et al., “Clinical significance of CD38 expression in chronic lymphocytic leukemia,” Blood, vol. 98, no. 9, pp. 2633–2639, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Rossi, S. Rasi, G. Fabbri et al., “Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia,” Blood, vol. 119, no. 2, pp. 521–529, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Wan and C. J. Wu, “SF3B1 mutations in chronic lymphocytic leukemia,” Blood, vol. 121, no. 23, pp. 4627–4634, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Puiggros, G. Blanco, and B. Espinet, “Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go,” BioMed Research International, vol. 2014, Article ID 435983, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Ripolles, M. Ortega, F. Ortuno et al., “Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia,” Cancer Genetics and Cytogenetics, vol. 171, no. 1, pp. 57–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Swords, J. Bruzzi, and F. Giles, “Recent advances in the diagnosis and therapy of Richter’s syndrome,” Medical Oncology, vol. 24, no. 1, pp. 17–32, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. M. A. Attia, N. A. Nosair, A. Gawally, G. Elnagar, and E. M. Elshafey, “HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic leukemia,” Acta Haematologica, vol. 132, no. 1, pp. 53–58, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Van Damme, E. Crompot, N. Meuleman et al., “Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients,” Epigenetics, vol. 9, no. 10, pp. 1374–1381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. C. K. Kontos, P. G. Adamopoulos, S. G. Papageorgiou, V. Pappa, and A. Scorilas, “mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients,” Clinical Chemistry and Laboratory Medicine, vol. 54, no. 2, pp. 315–324, 2016. View at Publisher · View at Google Scholar · View at Scopus
  59. S. G. Papageorgiou, C. K. Kontos, V. Pappa et al., “The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker,” The Oncologist, vol. 16, no. 9, pp. 1280–1291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Stamatopoulos, M. Van Damme, E. Crompot et al., “Opposite prognostic significance of cellular and serum circulating microRNA-150 in patients with chronic lymphocytic leukemia,” Molecular Medicine, vol. 21, pp. 123–133, 2015. View at Google Scholar
  61. H. C. Lai, Y. C. Wang, M. H. Yu et al., “DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia,” Gynecologic Oncology, vol. 135, no. 3, pp. 552–559, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. M. C. Kyrtsonis, K. Sarris, E. Koulieris et al., “Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia,” BioMed Research International, vol. 2014, Article ID 159632, 5 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. M. S. Truger, S. Jeromin, S. Weissmann et al., “Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 168, no. 1, pp. 153–156, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Pflug, J. Bahlo, T. D. Shanafelt et al., “Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia,” Blood, vol. 124, no. 1, pp. 49–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. S. M. Rapti, C. K. Kontos, I. N. Papadopoulos, and A. Scorilas, “Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 8, pp. 1217–1227, 2014. View at Publisher · View at Google Scholar · View at Scopus